/C O R R E C T I O N -- Eli Lilly and Company/

About this update from Eli Lilly And Company

In the news release, Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment, issued July 9, 2026 by Eli Lilly and Company over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer's disease Research spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly's 35-year commitment to Alzheimer's disease science INDIANAPOLIS, July 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease. Key Presentations at AAIC 2026 New Clinical Evidence on Kisunla (donanemab-azbt) On July 15, a Developing Topics Session, Donanemab in Early Symptomatic Alzheimer's Disease: Evidence to Address Clinical Questions, will present new insights from TRAILBLAZER-ALZ 6 and the TRAILBLAZER-ALZ 2 long-term extension. Findings include new data on safety through modified titration and corticosteroid pretreatment as well as long-term extension evidence on biomarkers and the potential durability of clinical benefit. Advancing Diagnostics Also on July 15, Samantha Burnham, Ph.D., senior research scientist, Eli Lilly and Company, will present data showing P-tau217 blood biomarker assays demonstrated strong rule-in performance comparable to amyloid PET for identifying Alzheimer's disease pathology in cognitively unimpaired individuals. Though blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, the results generate support for a potentially scalable, accessible alternative to specialized imaging in the future.

View stock analysis, news, and events for Eli Lilly And Company